2020 Was a Breakout Year for Crispr

2020 Was a Breakout Year for Crispr

The pandemic sped up the need for such tests. This summer, the FDA authorized two Crispr-based tests, both for detecting SARS-CoV-2. Boston-based Sherlock Biosciences received the green light for its test in May, and the Bay Area’s Mammoth Biosciences followed in August. It marked the first time the FDA has allowed a Crispr-based diagnostic tool […]

Lascia un commento

Il tuo indirizzo email non sarà pubblicato. I campi obbligatori sono contrassegnati *

This site uses Akismet to reduce spam. Learn how your comment data is processed.